Economic assessment of the benefits in question is facilitated by the fact that a public health programme designed to prevent a disorder matures over time, in that it approaches a steady state, where the number of years of life gained each year without the disorder becomes constant. In order to decide whether the programme is justified, all that is necessary is to compare the constant annual cost of the programme with the constant annual monetary value of the benefits. If the latter is limited to the direct financial saving, and is reckoned to exceed the former, the programme is financially more than justified. Even if this condition is not met, the programme may still be considered socially worthwhile, because of indirect monetary value assigned to the benefit -for example, an annual amount for each year of life gained without the disorder that has been prevented.
It also needs to be recognized that the annual financial value of the benefit arising from a preventive programme may start to exceed the annual cost well before the steady state is attained. Until that crossover point is reached, the costs exceed the benefits, albeit in gradually diminishing amounts. The value of the programme should be judged by the steady state numbers, accepting that costs may exceed benefits in the early years.
At no stage in this analysis does the notion of discounting -converting future financial benefits into lesser present values -have any place. It is clear that the application of standard investment decision procedures to preventive public health programmes is inappropriate and should be abandoned.
